Q1 - Hepatic Encephalopathy: First-Line Therapy

• Neither is correct as true first-line - Lactulose is the established first-line treatment.
• Dietary protein restriction is outdated and no longer recommended - it worsens malnutrition in cirrhotic patients.
• Rifaximin is used as an add-on to lactulose or for secondary prevention of recurrent episodes, not as monotherapy first-line.

Washington Manual: "Lactulose, 15-45 mL PO bid-qid, is the first choice for treatment of hepatic encephalopathy." Rifaximin is listed alongside neomycin and metronidazole as adjunctive antibiotics.

Q2 - Macrocytic Anemia in a Software Engineer (MCV 120)

• MCV of 120 fL = macrocytic/megaloblastic anemia
• The history is critical: poor diet, junk food, low fruits and vegetables - this points to nutritional folate deficiency (folate is abundant in leafy greens, fruits)
• Cyanocobalamin (B12) deficiency is also macrocytic but typically presents with neurological features (subacute combined degeneration of cord), and B12 is found in animal products - there's no strict vegan history here
• Folate deficiency is more rapidly acquired from poor diet (body stores last only 3-4 months vs B12 stores lasting 3-5 years)

Textbook of Family Medicine: "Vitamin B12 or folate deficiency may be suspected when a macrocytic anemia (MCV >100 fL) is present." The dietary history of low fruits/vegetables clinches folate deficiency.

Q3 - Stroke with PFO in a 35-Year-Old

• A patent foramen ovale allows communication between right and left atrium
• A venous thrombus (deep vein thrombosis, for example) can cross from the right side to the left side of the heart through the PFO
• This clot then enters the systemic circulation and can embolize to cerebral arteries, causing ischemic stroke
• This right-to-left shunting of a venous clot into the arterial system = paradoxical embolism

• Atherosclerotic embolism: unlikely in a 35-year-old with no cardiovascular risk factors mentioned
• Atrial fibrillation: no AF on echo - PFO was the finding
• Vasculitis: no supporting features

Q4 - Hypertensive Emergency with Myocardial Ischemia

Brenner and Rector's The Kidney: "Intravenous nitroglycerin may be the drug of choice in the treatment of patients with moderate hypertension associated with coronary ischemia because it provides collateral coronary vasodilation."

• Nitroprusside (c) can cause coronary steal phenomenon - it dilates non-ischemic coronary vessels preferentially, worsening ischemia in affected territories. Avoid in MI/ischemia.
• Hydralazine causes reflex tachycardia - worsens myocardial oxygen demand.
• Nicardipine + esmolol (d) - esmolol (beta-blocker) reduces heart rate and oxygen demand, and nicardipine lowers BP. This combination is actually acceptable for hypertensive emergency with ischemia.

Q5 - Essential Thrombocythemia, JAK2+, Platelets >10 lac, No Prior Thrombosis, Age 60

• High risk = age >60 years AND JAK2V617F mutation (each independently scores high)
• This patient is 60 years old + JAK2+ = High risk regardless of no prior thrombosis
• High-risk ET requires cytoreduction (Hydroxyurea is first-line) plus low-dose aspirin

Goldman-Cecil Medicine: High-risk ET = low-dose aspirin + cytoreduction; hydroxyurea is the cytoreductive agent of choice.

Q6 - GLP-1 Agonist Side Effects: All EXCEPT

• Nausea - very common (correct side effect)
• Diarrhea - common (correct side effect)
• Bloating/abdominal discomfort - common (correct side effect)
• Weight LOSS - this is a beneficial effect, NOT weight gain

Sleisenger and Fordtran's: "GI side effects, including nausea and diarrhea, may contribute to the weight loss seen with these medications."

Q7 - Hypercalcemia Management: All EXCEPT

• IV Normal saline (a) - aggressive hydration is the cornerstone of acute hypercalcemia treatment (increases urinary calcium excretion)
• IV Bisphosphonates (d) - (zoledronate, pamidronate) inhibit osteoclast activity, mainstay for malignancy-related hypercalcemia
• Hemodialysis (c) - used in severe/refractory hypercalcemia, especially with renal failure
• Calcitonin, corticosteroids, denosumab - also used

Summary Table

Q8 - Metabolic Syndrome: Which is NOT a Feature?

• Central/abdominal obesity (waist circumference threshold)
• Raised triglycerides (≥150 mg/dL)
• Low HDL cholesterol (not raised LDL)
• Raised blood pressure (≥130/85 mmHg)
• Raised fasting glucose / insulin resistance

Robbins Pathologic Basis of Disease: Metabolic syndrome criteria include "triglycerides ≥1.695 mmol/L and HDL-C ≤0.9 mmol/L (male), central obesity: waist-hip ratio >0.90..."

Q9 - Isolated 3rd Nerve Palsy WITH Pupil Sparing

Kanski's Clinical Ophthalmology: "Microvascular disease associated with hypertension and diabetes are the most common cause of third nerve palsy... the pupil may be spared." Rosen's Emergency Medicine: "Pupil-sparing complete CN III palsy - because microvascular ischemia to CN III."

Q10 - Indirect (Unconjugated) Hyperbilirubinemia: All EXCEPT

• Gilbert syndrome - impaired hepatic uptake/conjugation ✓
• Malaria - hemolysis → excess unconjugated bilirubin ✓
• Autoimmune hemolytic anemia - hemolysis → unconjugated bilirubin ✓
• Rotor syndrome - this causes conjugated (direct) hyperbilirubinemia ✗

Quick Compendium of Clinical Pathology: "Dubin-Johnson syndrome, Rotor syndrome → conjugated hyperbilirubinemia" Washington Manual: "Unconjugated hyperbilirubinemia occurs as a result of excessive bilirubin production (hemolysis, hemolytic anemias)..."

Q11 - Acute Liver Failure: All EXCEPT

• Hepatitis A - can cause acute liver failure, especially in elderly/those with chronic liver disease ✓
• Hepatitis B - well-established cause of fulminant hepatic failure ✓
• Autoimmune liver disease - can present as acute liver failure ✓
• Hepatitis C - rarely if ever causes acute liver failure; HCV is predominantly a chronic infection

Goodman & Gilman's: "Hepatitis B and C may or may not cause symptoms..." HCV is known for chronicity, not acute fulminant failure.

Q12 - Microcytic Hypochromic Anemia: All EXCEPT

• Iron deficiency anemia - classic cause ✓
• Thalassemia - classic cause ✓
• Sideroblastic anemia - microcytic or dimorphic picture ✓
• Folic acid deficiency - causes macrocytic (megaloblastic) anemia, not microcytic

Q13 - Precipitants of Hepatic Encephalopathy: All EXCEPT

• Sedatives and antidepressants - suppress CNS, worsen encephalopathy ✓
• Diuretics and paracentesis - cause electrolyte imbalance, dehydration ✓
• Sepsis/infection - major precipitant (increases protein catabolism, ammonia) ✓
• GI bleeding - blood in gut = protein load → ammonia
• Constipation, renal failure, dietary protein excess

Q14 - Portal Hypertension Features

• Splenomegaly - from congestion due to increased portal pressure ✓
• Ascites
• Varices (esophageal/gastric)
• Caput medusae
• Thrombocytopenia (splenic sequestration)

Harrison's: "Radiologic signs of portal hypertension include ascites, splenomegaly, and portal-systemic collateral vessels."

Q15 - Hepatitis B Transmission: Risk Factors EXCEPT

• Vertical transmission (mother to child, perinatal) ✓
• Needle stick injury ✓
• Sharing toothbrush/razor (contact with blood/body fluids) ✓
• Sexual contact ✓

Robbins: "Hepatitis A - Route of transmission: Fecal-oral (contaminated food or water); HBV - Parenteral, sexual contact, perinatal."

Q16 - Hemoglobin-Oxygen Dissociation Curve Affected By

• CO2 (increased CO2 → right shift) ✓
• H+ / pH (acidosis → right shift) ✓
• Temperature (increased temp → right shift) ✓
• 2,3-DPG (increased → right shift) ✓

Guyton and Hall Physiology: "Three factors shift the curve to the right: increased CO2, increased H+ concentration (decreased pH), and increased temperature."

Q17 - Target Cells (Codocytes) Are Seen In

• Post-splenectomy (a) ✓ - spleen no longer remodels excess membrane
• Iron deficiency (b) ✓ - excess membrane relative to Hb content
• Hypothyroidism (c) ✓ - seen occasionally
• Also: liver disease, thalassemia, HbC disease, HbSC disease

Q18 - Oral Anticoagulants: All EXCEPT

• Warfarin (a) - oral, vitamin K antagonist ✓
• Dabigatran (c) - oral direct thrombin inhibitor ✓
• Apixaban (d) - oral direct factor Xa inhibitor ✓

Q19 - Key Feature of Complete Heart Block

• P waves and QRS complexes are completely dissociated - no relationship
• Atria fire at sinus rate; ventricles fire at a slow escape rate (30-45 bpm)
• Sinus bradycardia (a) - wrong; the sinus node fires normally but impulses don't reach the ventricles
• Prolonged PR interval (c) - this is 1st degree heart block, not complete block

Q20 - Contraindications to Thrombolytic Therapy: All EXCEPT

• Uncontrolled hypertension (a) - absolute contraindication ✓
• Intracranial bleeding (c) - absolute contraindication ✓
• Prior hemorrhagic stroke, active internal bleeding, recent surgery/trauma

Summary Table

UDCA (Ursodeoxycholic Acid) - Complete Clinical Guide

Mechanism of Action

• Replacing toxic hydrophobic bile acids in the bile acid pool
• Stimulating hepatocellular and cholangiocellular secretion (choleretic effect)
• Cytoprotection - anti-apoptotic effects on hepatocytes and cholangiocytes
• Immunomodulation - reduces aberrant MHC class I expression on hepatocytes
• Stabilizes cell membranes against toxic bile acid damage

1. PRIMARY BILIARY CHOLANGITIS (PBC) - MAIN INDICATION

Who to Start

• ALL patients with PBC who have abnormal liver enzyme values, regardless of histologic stage (AASLD/EASL Class I recommendation)
• Start at diagnosis - do not wait for symptoms or advanced disease
• Early initiation = better long-term outcomes

Dose

• 13-15 mg/kg/day orally - this is the evidence-based optimal dose
• Can be given as a single daily dose or in 2-3 divided doses
• Some patients tolerate divided doses better if GI side effects occur
• Why this dose? The 13-15 mg/kg/day range has been shown superior to both lower doses (5-7 mg/kg/day - insufficient effect) and higher doses (23-25 mg/kg/day - no additional benefit, more side effects)
• Duration: Lifelong if tolerated

EASL PBC Guidelines: "The optimum dose is 13-15 mg/kg per day... In PBC, a dose of 13-15 mg/kg/day has been reported to be superior to 5-7 mg/kg/day or 23-25 mg/kg/day." AASLD 2018 Practice Guidance: "UDCA in a dose of 13-15 mg/kg/day orally is recommended for patients with PBC who have abnormal liver enzyme values regardless of histologic stage."

How to Monitor Response (Assess at 6-12 months)

UDCA Response Criteria in PBC (AASLD/EASL Validated)

• Paris I: AST >2x ULN = inadequate response
• Paris II: AST >1.5x ULN = inadequate response
• If AST remains above these levels after 1 year of UDCA at 13-15 mg/kg/day, the patient needs second-line therapy

What to Do with Inadequate UDCA Responders

1. Obeticholic acid (OCA) - Add 5 mg/day, titrate to 10 mg/day if tolerated (second-line, AASLD-recommended). Contraindicated in decompensated cirrhosis.
2. Fibrates (bezafibrate 400 mg/day or fenofibrate) - Off-label, emerging evidence, avoid in decompensated disease
3. Seladelpar (PPAR-delta agonist) - recently approved in some regions (2024)
4. Liver transplant assessment in cirrhotic/decompensated patients

2. PRIMARY SCLEROSING CHOLANGITIS (PSC)

Who to Start

• Not routinely recommended - no proven survival benefit (AASLD 2022 Practice Guidance)
• Consider in selected patients who have:
  • Persistently elevated ALP or GGT
  • Not eligible for or interested in clinical trials

Dose

• 13-23 mg/kg/day (intermediate dose range)
• Assess response at 12 months: continue only if meaningful reduction or normalization of ALP (or GGT in children) is seen

What NOT to Do in PSC

• HIGH DOSE UDCA (>25-30 mg/kg/day) is CONTRAINDICATED - a landmark RCT (Lindor 2009) found high-dose UDCA increased risk of death, liver transplantation, and colorectal dysplasia
• Do not use routinely as standard of care

AASLD 2022 PSC Guidance: "In patients not eligible or interested in clinical trials with persistently elevated ALP or GGT, UDCA 13-23 mg/kg/day can be considered for treatment and continued if there is a meaningful reduction or normalization in ALP."

3. INTRAHEPATIC CHOLESTASIS OF PREGNANCY (ICP)

Who to Start

• Pregnant women with pruritus + elevated serum bile acids >10 μmol/L and elevated ALT/AST in the 2nd-3rd trimester
• Severe ICP: bile acids >40 μmol/L - higher fetal risk, treatment urgent
• Note: UDCA is NOT approved for the first trimester (insufficient safety data)

Dose

• 10-15 mg/kg/day in divided doses
• Start as soon as diagnosis is confirmed in 2nd/3rd trimester
• Continue until delivery

Evidence

• Resolves pruritus ✓
• Reduces serum bile acid levels ✓
• Decreases ALT/AST ✓
• Reduces adverse maternal and fetal outcomes ✓

4. GALLSTONE DISSOLUTION

Who to Start (Strict Selection Criteria)

• Radiolucent (non-calcified) cholesterol gallstones
• Stone size ≤20 mm (best results ≤5 mm - ~81% dissolution rate)
• Patient must be a poor surgical candidate (comorbidities, anesthesia risk, patient refusal)
• Gallbladder must be functioning (gallbladder contraction >60% on ultrasound stimulation test)
• Not suitable for pigment stones, calcified stones, or non-functioning gallbladder

Dose

• 8-12 mg/kg/day in divided doses
• Most patients: 600-900 mg/day in 2 divided doses after meals (take one dose after evening meal)
• Duration: 6-24 months, depending on stone size
• Reassess by ultrasound every 6 months
• Recurrence rate after discontinuation: ~50% at 5 years

5. CYSTIC FIBROSIS-ASSOCIATED LIVER DISEASE

Who to Start

• Children aged 6-18 years with hepatobiliary involvement in cystic fibrosis
• Licensed indication in several countries

Dose

• 20 mg/kg/day in divided doses

6. CONDITIONS WHERE UDCA is NOT RECOMMENDED

Common clinical mistake: Using UDCA empirically for fatty liver or non-specifically raised liver enzymes. UDCA is a disease-specific drug, not a general hepatoprotective agent.

Summary: Doses at a Glance

Monitoring Parameters

• Liver tests: AST, ALT, ALP, GGT, bilirubin, albumin, INR
• Baseline and at 3, 6, 12 months, then annually
• In PBC: also check platelet count and elastography (Fibroscan) to assess for progressive fibrosis
• If no biochemical improvement after 6-12 months at correct dose, assess for non-compliance first, then consider inadequate response

Side Effects

• Generally very well tolerated
• Mild diarrhea/loose stools (most common)
• Nausea
• Pruritus (rarely worsens transiently at initiation in PBC)
• High-dose UDCA in PSC: paradoxical harm - increased risk of adverse clinical outcomes

Contraindications

• Obstructive cholestasis (risk of biliary disruption)
• First trimester of pregnancy
• High-dose (>25-30 mg/kg/day) in PSC - absolutely contraindicated

• AASLD 2018 PBC Practice Guidance
• EASL Clinical Practice Guidelines PBC 2017
• AASLD 2022 PSC Practice Guidance
• StatPearls - Ursodeoxycholic Acid
• World Gastroenterology Organisation: PBC New Treatment Goals (PMID: 37399238, 34102008)